Progesterone after mifepristone, for women whose decision has changed after commencing a medical termination of pregnancy - a pilot clinical trial
- Conditions
- Pregnancy continuation after mifepristoneReproductive Health and Childbirth - Other reproductive health and childbirth disordersReproductive Health and Childbirth - Abortion
- Registration Number
- ACTRN12620000596909
- Lead Sponsor
- niversity of New England
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 52
Women who:
- have ingested mifepristone within the last 72 hours to initiate MTOP
- have not taken any misoprostol;
- have no contraindications for use of progesterone, including known allergy or hypersensitivity to progesterone or to any of the excipients, severe hepatic dysfunction, undiagnosed vaginal bleeding, known missed miscarriage or ectopic pregnancy, mammary or genital tract carcinoma, thromboembolic disorders, thrombophlebitis, cerebral haemorrhage, or porphyria.
- live in Australia;
- provide the name of their usual or nominated medical practitioner; and
- understand English, or utilise the assistance of an accredited interpreter if appropriate.
Women who
- are unable to take their first dose of progesterone within 72 hours of taking mifepristone;
- are not living in Australia;
- wish to continue with MTOP and take misoprostol; or
- declined permission for communication between the trial coordinator and their usual or nominated medical practitioner regarding trial participation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Viable pregnancy as determined by ultrasound.[Two weeks after intervention commencement.]
- Secondary Outcome Measures
Name Time Method